ASX - By Stock
|
PAR Biotech |
Re:
Timelines and Capital Requirements
|
|
Weazel
|
4 |
1.9K |
9 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
4
|
1.9K
|
9
|
|
ASX - By Stock
|
BTH |
Re:
Ann: Rejection of NBIO
|
|
Weazel
|
78 |
35K |
1 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
78
|
35K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
6 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
507
|
118K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
5 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
507
|
118K
|
5
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical Expands Portfolio with Unique Dermal Matrix
|
|
Weazel
|
47 |
14K |
0 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
47
|
14K
|
0
|
|
ASX - By Stock
|
BTH |
Re:
Ann: Rejection of NBIO
|
|
Weazel
|
78 |
35K |
3 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
78
|
35K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Weazel
|
100 |
29K |
7 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
100
|
29K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Weazel
|
100 |
29K |
6 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
100
|
29K
|
6
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
2 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
507
|
118K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Weazel
|
4.4K |
2.0M |
1 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Sharewise Presentation 22/7/24
|
|
Weazel
|
139 |
42K |
3 |
28/07/24 |
28/07/24 |
ASX - By Stock
|
139
|
42K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
11 |
28/07/24 |
28/07/24 |
ASX - By Stock
|
507
|
118K
|
11
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
7 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
507
|
118K
|
7
|
|
ASX - By Stock
|
AVH |
Re:
ReCell Go Is Massive
|
|
Weazel
|
161 |
58K |
4 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
161
|
58K
|
4
|
|
ASX - By Stock
|
AVH |
Re:
ReCell Go Is Massive
|
|
Weazel
|
161 |
58K |
10 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
161
|
58K
|
10
|
|
ASX - By Stock
|
AVH |
Re:
RECELL Clinical Education (Warning: Graphic Medical Images)
|
|
Weazel
|
98 |
44K |
7 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
98
|
44K
|
7
|
|
ASX - By Stock
|
BTH |
Re:
Ann: Rejection of NBIO
|
|
Weazel
|
78 |
35K |
1 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
78
|
35K
|
1
|
|
ASX - By Stock
|
BTH |
Re:
Ann: Rejection of NBIO
|
|
Weazel
|
78 |
35K |
1 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
78
|
35K
|
1
|
|
ASX - By Stock
|
AVH |
Re:
ReCell Go Is Massive
|
|
Weazel
|
161 |
58K |
4 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
161
|
58K
|
4
|
|
ASX - By Stock
|
AVH |
Re:
ReCell Go Is Massive
|
|
Weazel
|
161 |
58K |
2 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
161
|
58K
|
2
|
|
ASX - By Stock
|
AVH |
Re:
ReCell Go Is Massive
|
|
Weazel
|
161 |
58K |
3 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
161
|
58K
|
3
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
3 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
36
|
12K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Sharewise Presentation 22/7/24
|
|
Weazel
|
139 |
42K |
2 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
139
|
42K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Sharewise Presentation 22/7/24
|
|
Weazel
|
139 |
42K |
9 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
139
|
42K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Weazel
|
4.4K |
2.0M |
2 |
21/07/24 |
21/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
2
|
|
ASX - By Stock
|
EYE |
Re:
Nova Eye Medical (EYE) Chart Thread
|
|
Weazel
|
342 |
109K |
11 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
342
|
109K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Weazel
|
4.4K |
2.0M |
16 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
16
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
3 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
36
|
12K
|
3
|
|
ASX - By Stock
|
PAR Medicine |
Re:
LiveStream: Paradigm Biopharma (ASX:PAR) pursuing FDA review
|
|
Weazel
|
16 |
10K |
6 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
16
|
10K
|
6
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
4 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
36
|
12K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Weazel
|
4.4K |
2.0M |
18 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
18
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Weazel
|
4.4K |
2.0M |
6 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
6
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
1 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
36
|
12K
|
1
|
|
ASX - By Stock
|
AVH |
Re:
ReCell Go Is Massive
|
|
Weazel
|
161 |
58K |
3 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
161
|
58K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
2 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
507
|
118K
|
2
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
2 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
507
|
118K
|
2
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical to Announce Second Quarter 2024 Results
|
|
Weazel
|
61 |
24K |
9 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
61
|
24K
|
9
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
4 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
507
|
118K
|
4
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
1 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
36
|
12K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
1 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
507
|
118K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
4 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
507
|
118K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Weazel
|
4.4K |
2.0M |
7 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
7
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical to Announce Second Quarter 2024 Results
|
|
Weazel
|
61 |
24K |
11 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
61
|
24K
|
11
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
2 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
36
|
12K
|
2
|
|
ASX - By Stock
|
BTH |
Re:
Chart
|
|
Weazel
|
36 |
12K |
0 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
36
|
12K
|
0
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
2 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
507
|
118K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
PARate Day 2024 - scurvy dogs o' the ASX
|
|
Weazel
|
124 |
42K |
3 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
124
|
42K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
1 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
507
|
118K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
2 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
507
|
118K
|
2
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Weazel
|
507 |
118K |
6 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
507
|
118K
|
6
|
|